Data / Form D filings / NephroDI Therapeutics, Inc.
NephroDI Therapeutics, Inc.: Form D filings
NephroDI Therapeutics, Inc., a pharmaceuticals company in Seattle, WA, filed 2 Form D notices with the SEC between 2021 and 2024. The latest, on June 18, 2024, reports $2 million sold of a $4 million offering to 2 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2200 32ND AVE W, Seattle, WA, 98199
- Phone
- (206) 696-0546
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1840655
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jun 18, 2024 | New notice | $3,999,999 | $2,000,000 | $1,999,999 | 2 | Jun 11, 2024 | sec.gov |
| Feb 23, 2021 | New notice | $1,600,018 | $1,600,018 | 1 | Feb 11, 2021 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Rachael Hagan | Executive Officer, Director | |
| Michael Grissinger | Director | |
| Bibhash M. Mukhopadhyay | Director | |
| Jeff M. Sands, M.D. | Executive Officer |
Other pharmaceuticals companies in Washington that filed recently
- Aptevo Therapeutics Inc. $3.5 million · Aug 26, 2026
Every Form D from the week of Jun 17, 2024 · All recent filings in Washington · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what NephroDI Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.